New cellular flaw found in some virulent breast cancers

[RhondaH]

http://www.innovations-report.com/html/reports/life_sciences/report-54024.html

Rhonda

[RobinP]

Thanks for the various links and posts on this topic of p27 and cyclin D and Flavinoid. What really gets me about this posted article is the following: "ONlY a 13% survival over 7 years for this co expresion of her2 and cyclinD." It is my understanding that essentially everyone that is her2+ is + cyclinD. These outrageous poor survival rates are discouraging to say the least. Let's hope this study on survival rates was small and insignificant. I've been looking but haven't seen the study for the 13% survival, have you?

[RhondaH]

I found the email address for Peter Sicinski, MD, PhD of Dana-Farber who led the team and sent him an email asking how we might obtain a copy of the study. Take care and God bless

Rhonda

[RobinP]

Why didn't my post show up above????

[RobinP]

Good work Rhonda on your contact to Dana Farber. Please let us know what you find out. Thanks too for all these posts on cyclin D and her2.

[Becky]

You may find out that they were using subjects that were Stage 4 but very, very ill. We all know that overall, the survival rates of even triple negatives is much much better than 13% when looking at it via (even) traditional staging mechanisms and then subtracting 10% or 15% because of Her2+ or triple negative (then adding back the 50% difference if using Herceptin as an adjuvant). So... it will be interesting to see the test subjects criteria.


Robin - I owe you an email and will do so this evening.

Best regards

Becky

[RhondaH]

Dear Rhonda,
Thank you very much for your email message. I must let you know straight away
that I am not a clinician - I am only a scientist.
It is my understanding that the overwhelming majority of HER2+ patients do NOT
overexpress cyclin D1. Only a small fraction of HER2+ tumors also overexpress
cyclin D1. According to only one study, these HER2+, cyclin D1-overexpressing
patients have poor survival rates. The study has not been repeated on a larger
population, and it has not been independently confirmed by other investigators.

In any case, I suggest you address your questions to a physician, not a
scientist like myself. One of the co-authors on our paper, Dr. Lyndsay Harris
from our Institute works with breast cancer patients. Her email address:

hoffman_brown@msn.com ("]lyndsay_harris@dfci.harvard.edu[/url]

FAX: (617) 632.3478

I hope this will be helpful.
With my very best wishes for you,
Peter Sicinski

> -- --------
> From: rhonda r hoffman
> Sent: Thursday, January 19, 2006 10:42 AM
> To: Sicinski, Peter; [url=")
> Subject: Regarding article on "New cellular flaw found in some virulent
> breast cancers
>
> I am an almost 1 year Stage 1, ER/PR-, Her2+ (3.16 fish) breast cancer
> survivor and I posted the article on your recent findings on the HER2support
> group board and MANY of our group have found the 13% survival rate quite
> disturbing. Could you PLEASE give us more information on your findings AND
> or direct us on how we may obtain a copy of the study? Thank you.
>
> Rhonda Hoffman
>
> New cellular flaw found in some virulent breast cancers
>
> ------------------------------------------------------------------------------
> --
>
> http://www.innovations-report.com/h...port-54024.html ("")
>
> Rhonda
> ***
> Posts: 117 ONlY a 13% survival over 7 years for this co expresion of her2
> and overactive cyclin
>
> ------------------------------------------------------------------------------
> --
>
> Thanks for the various links and posts on this topic of p27 and cyclin D and
> Flavinoid. What really gets me about this posted article is the following:
> "ONlY a 13% survival over 7 years for this co expresion of her2 and
> cyclinD." It is my understanding that essentially everyone that is her2+ is
> + cyclinD. These outrageous poor survival rates are discouraging to say the
> least. Let's hope this study on survival rates was small and insignificant.
> I've been looking but haven't seen the study for the 13% survival, have you?
> __________________
> Fondly,
> Robin
>
>
>
>

[RobinP]

Nice work Rhonda, thanks for the posted response. So are you going to contact Dr. Harris to for further information on the study size and percentage of her2s that are cylinD positive? Also, where do you buy the Sichuan Peppercorns that are suppose to decrease Cyclin D? Thanks Rhonda for all of your hard work and input on this topic.

[RhondaH]

I already sent Dr. Harris an email. I found the szechuan peppers at Penzey Spices (http://www.penzeys.com/cgi-bin/penzeys/p-penzeysszechuanpeppercorns.html) we have a store nearby. They actually are QUITE good (have been using it in place of regular pepper...a little KICK to it). Take care and God bless

Rhonda

[Unregistered]

How does one know if they have Cyclin D? I was dx with stage 1 er/pr- and her2+++ in 7/05 and never heard of cyclin D.
I thought I had a good chance of beating bc with herceptin and the chemo/rads I'm undergoing, now this is discouraging news.....13% survival rate!
Rocky

[Unregistered]

I just saw this article yesterday, printed it out and thought to myself, before I do anything further, I will check in with the her2group, knowing that you'd be on top of the situation. You people are awesome.

And I have the same question. Does anyone know how we get tested for the cyclin d?

Gina

[RhondaH]

a followup email asking here your question.

Rhonda

[RhondaH]

Hi Rhonda,I wish the testing were available commercially but it hasn't been validated yet.We are working hard to do this! At the moment, while our paper makes animportant observation, we are not yet aware how Cyclin D1 influences response totherapy. In some cases factors that make the prognosis worse don't influence thebenefit of therapy, in other cases they do. In other words, the therapy mayremove the negative prognosis. We hope to learn more about this very soon!I have just joined the Yale Cancer Center as Director of the Breast CancerProgram. If I can be of any help, please feel free to contact me.lyndsay.harris@yale.edu (http://by101fd.bay101.hotmail.msn.com/cgi-bin/compose?curmbox=00000000-0000-0000-0000-000000000001&a=40b67c47303561a909a695970c6d09e3124da71738eea107 d4967ba2955ad88d&mailto=1&to=lyndsay.harris@yale.edu&msg=6BE57C94-2C27-4891-9486-1E807DB3C0FB&start=0&len=2379&src=&type=x).bestLyndsay N. Harris, MDAssociate Professor of MedicineDirector, Breast Disease UnitYale School of Medicine118 Fitkin BldgNew Haven, CTPhone: 203-737-1600Fax: 203-785-3788________________________________From: rhonda r hoffman [mailto:hoffman_brown@msn.com (http://by101fd.bay101.hotmail.msn.com/cgi-bin/compose?mailto=1&msg=6BE57C94-2C27-4891-9486-1E807DB3C0FB&start=0&len=2379&src=&type=x&to=hoffman_brown@msn.com&cc=&bcc=&subject=&body=&curmbox=00000000-0000-0000-0000-000000000001&a=40b67c47303561a909a695970c6d09e3124da71738eea107 d4967ba2955ad88d)]Sent: Mon 1/23/2006 12:42 PMTo: Harris, Lyndsay N.,M.D.Subject: Cyclin dDr. Harris, I have a followup question to my earlier email:Does anyone know how we get tested for the cyclin d?Sincerely, Rhonda Hoffman